U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O3
Molecular Weight 416.6365
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CALCITRIOL

SMILES

[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C)[C@H](C)CCCC(C)(C)O

InChI

InChIKey=GMRQFYUYWCNGIN-NKMMMXOESA-N
InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H44O3
Molecular Weight 416.6365
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 2
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/calcitriol.html http://www.wikidoc.org/index.php/Calcitriol_(oral)

Trans-calcitriol or Calcitriol Impurity A, is the impurity of Calcitriol. Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR). Calcitriol Impurity A is the physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.

CNS Activity

Curator's Comment: Circulating calcitriol can cross the blood brain barrier to a limited extent, and the brain itself may be able to synthesize calcitriol.

Originator

Curator's Comment: First obtained from chick intestine and designated as metabolite 4B

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ROCALTROL

Approved Use

Predialysis Patients Calcitriol Capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

Launch Date

2.72159998E11
Preventing
ROCALTROL

Approved Use

Predialysis Patients Calcitriol Capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

Launch Date

2.72159998E11
Primary
VECTICAL

Approved Use

VECTICAL Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older.

Launch Date

2.72159998E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1100 pg/mL
38 μg 3 times / week multiple, oral
dose: 38 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PACLITAXEL
CALCITRIOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
73.1799999999999 pg/mL
3 ug/g 2 times / day multiple, topical
dose: 3 ug/g
route of administration: topical
experiment type: multiple
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
75.74 pg/mL
3 ug/g single, topical
dose: 3 ug/g
route of administration: topical
experiment type: single
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8100 pg × h/mL
38 μg 3 times / week multiple, oral
dose: 38 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PACLITAXEL
CALCITRIOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
737.74 pg*h/mL
3 ug/g 2 times / day multiple, topical
dose: 3 ug/g
route of administration: topical
experiment type: multiple
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
764.74 pg*h/mL
3 ug/g single, topical
dose: 3 ug/g
route of administration: topical
experiment type: single
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
549.29 pg*h/mL
3 ug/g 2 times / day multiple, topical
dose: 3 ug/g
route of administration: topical
experiment type: multiple
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
575.12 pg*h/mL
3 ug/g single, topical
dose: 3 ug/g
route of administration: topical
experiment type: single
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
25 h
38 μg 3 times / week multiple, oral
dose: 38 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PACLITAXEL
CALCITRIOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of 1,25-dihydroxyvitamin D3 on the female reproductive system in rats.
1992 Aug
Potentiation of lipopolysaccharide-induced tumor necrosis factor-alpha expression by 1,25-dihydroxyvitamin D3.
1992 Dec 1
Hypercalcemia-induced renal insufficiency during therapy with dihydrotachysterol.
1999
Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity.
1999 Jan
Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors.
1999 Mar
22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
1999 Mar
A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea--a review.
2000
Zinc increases the activity of vitamin D-dependent promoters in osteoblasts.
2000 Apr 29
Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures.
2000 Dec
Association of transforming growth factor beta1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis.
2000 Mar
Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.
2000 Mar
24,25-dihydroxyvitamin D3 in combination with 1,25-dihydroxyvitamin D3 ameliorates renal osteodystrophy in rats with chronic renal failure.
2000 May
Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat.
2000 Sep 1
Effects of 1alpha,25-(OH)(2)D(3) on rat growth zone chondrocytes are mediated via cyclooxygenase-1 and phospholipase A(2).
2001
Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets.
2001 Apr
Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3.
2001 Dec
1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck.
2001 Jan
Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
2001 Jun 15
Failure of high doses of calcitriol and hypercalcaemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats.
2001 Mar
Dietary phosphorus deprivation induces 25-hydroxyvitamin D(3) 1alpha-hydroxylase gene expression.
2001 May
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.
2001 Nov
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.
2002 Feb
Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer.
2002 Jul
Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D.
2002 Jul
Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro?
2002 Mar
HL60 cells halted in G1 or S phase differentiate normally.
2002 Nov 15
Demonstration of UVB-induced synthesis of 1 alpha,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis.
2003 Apr
Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats.
2003 Aug
9-cis retinoic acid accelerates calcitriol-induced osteocalcin production and promotes degradation of both vitamin D receptor and retinoid X receptor in human osteoblastic cells.
2003 Aug 15
Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis.
2003 Aug 15
Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity.
2003 Sep 12
Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
2004 Aug
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
2004 Aug
Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth.
2004 Dec 20
Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis.
2004 Jul 8
Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients.
2004 May
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific.
2004 Nov 5
Calcium and calcitriol prophylaxis attenuates posttransplant bone loss.
2004 Oct 27
Role of uncoupling protein 2 (UCP2) expression and 1alpha, 25-dihydroxyvitamin D3 in modulating adipocyte apoptosis.
2004 Sep
Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels.
2005 Apr
Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4.
2005 Apr 1
1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
2005 Feb
Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative.
2005 Jan
Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation.
2005 Jan
Regulation of the human vitamin D3 receptor promoter in breast cancer cells is mediated through Sp1 sites.
2005 Jan 31
Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells.
2005 Jun
Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats.
2005 Mar
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.
2005 Mar
Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats.
2005 May
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
2005 Sep 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: The recommended initial dose of Calcitriol Injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered intravenously three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. Apply Calcitriol Ointment to affected areas twice daily, morning and evening. The maximum weekly dose should not exceed 200 grams. Calcitriol Ointment is not for oral, ophthalmic or intravaginal use.
Calcitriol can be administered orally either as a capsule (0.25 mcg or 0.50 mcg) or as an oral solution (1 mcg/mL).
Route of Administration: Other
CYP3A4 mRNA expression in LS180 cells treated with 100 nM of Calcitriol for 6 and 24 h was approximately 80- and 500-fold higher than the control.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:16:38 UTC 2023
Edited
by admin
on Wed Jul 05 23:16:38 UTC 2023
Record UNII
FXC9231JVH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCITRIOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
CALCITRIOL [MART.]
Common Name English
VECTICAL
Brand Name English
CALCITRIOL [VANDF]
Common Name English
ROCALTROL
Brand Name English
CALCIJEX
Brand Name English
CALCITRIOL [USP MONOGRAPH]
Common Name English
CALCITRIOL [EP MONOGRAPH]
Common Name English
(1S,3R,5Z,7E)-9,10-SECOCHOLESTA-5,7,10-TRIENE-1,3,25-TRIOL
Common Name English
CALCITRIOL [USP-RS]
Common Name English
RO-21-5535
Code English
CALCITRIOL [JAN]
Common Name English
RO-215535
Code English
Calcitriol [WHO-DD]
Common Name English
CALCITRIOL [HSDB]
Common Name English
CALCITRIOL [ORANGE BOOK]
Common Name English
calcitriol [INN]
Common Name English
1,25-DIHYDROXY VITAMIN D3
Common Name English
1,25-HYDROXYLATED VITAMIN D
Common Name English
1,25-DIHYDROXYVITAMIN D3
Common Name English
RO 21-5535
Code English
CALCITRIOL [USAN]
Common Name English
CALCITRIOL [MI]
Common Name English
9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL, (1.ALPHA.,3.BETA.,5Z,7E)-
Common Name English
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1α,3β,25-triol
Common Name English
1,25-DIHYDROXYCHOLECALCIFEROL, (1ALPHA)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000006996
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
WHO-VATC QD05AX03
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
NCI_THESAURUS C39713
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
LOINC 1649-3
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
LIVERTOX 140
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
NDF-RT N0000006996
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
WHO-ATC A11CC04
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
NDF-RT N0000006996
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
NDF-RT N0000006996
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
LOINC 14566-4
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
NDF-RT N0000175908
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
WHO-VATC QA11CC04
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
WHO-ATC D05AX03
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
NCI_THESAURUS C1934
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
Code System Code Type Description
IUPHAR
2779
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
ECHA (EC/EINECS)
250-963-8
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
PUBCHEM
5280453
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
SMS_ID
100000092790
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
WIKIPEDIA
CALCITRIOL
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
CHEBI
17823
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
MERCK INDEX
M2917
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB00136
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
RS_ITEM_NUM
1086301
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
MESH
D002117
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
EPA CompTox
DTXSID5022722
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
INN
4393
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
ChEMBL
CHEMBL846
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
DAILYMED
FXC9231JVH
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
DRUG CENTRAL
466
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
NCI_THESAURUS
C330
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
HSDB
3482
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
EVMPD
SUB06047MIG
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
RXCUI
1894
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY RxNorm
FDA UNII
FXC9231JVH
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
LACTMED
Calcitriol
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
CAS
32222-06-3
Created by admin on Wed Jul 05 23:16:38 UTC 2023 , Edited by admin on Wed Jul 05 23:16:38 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
DERIVATIVE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
PARENT -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
The conversion of calcidiol to calcitriol is catalyzed by the enzyme 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1).
METABOLITE INACTIVE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC